UroToday1d
Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
Reno, Nevada (UroToday.com) Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve ...
UroToday3d
ESMO 2024: Invited Discussant: CC-94676-PCA-001 and INSPIRE
(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a discussant presentation by Dr. Christopher Sweeney discussing two abstracts including “CC-94676-PCA-001: ...
UroToday4d
ESMO 2023: ARASTEP: Darolutamide + ADT in Patients with High-Risk BCR Prostate Cancer – A Phase 3 Study
(UroToday.com) The 2023 ESMO annual meeting included a trial in progress session on prostate cancer, featuring a presentation by Dr. Alicia Morgans discussing ARASTEP, a phase 3, randomized, ...
UroToday4d
Prostate cancer survivorship of Australian men living with prostate cancer: Patient support programs in Australia.
Treatment for prostate cancer (PC) is associated with adverse effects, especially in patients receiving androgen deprivation therapy (ADT). The Australian Government, non-governmental organisations ...
UroToday4d
Unusual Prostate-Specific Membrane Antigen (PSMA) Splenic Uptake in a Patient With Prostate Cancer.
There are many benefits to early detection of prostate cancer, including improved survival rates, less invasive treatment options, and better quality of life. Apart from traditional tests and imaging ...
UroToday4d
Location-based Radiology Report-Guided Semi-supervised Learning for Prostate Cancer Detection.
Prostate cancer is one of the most prevalent malignancies in the world. While deep learning has potential to further improve computer-aided prostate cancer detection on MRI, its efficacy hinges on the ...
UroToday4d
If Not Now, Then When? The Need for New Evidence in the Robotic Management of Upper Tract Urothelial Carcinoma - Beyond the Abstract
The current manuscript presented an overview of the existing challenges in robotic nephroureterectomy (RNU) for the treatment of upper tract urothelial carcinoma (UTUC) and outlined a multicentric ...
UroToday4d
Treatment Preferences and Tradeoffs Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma - Expert Commentary
With the expanding therapeutic options for patients with locally advanced or metastatic urothelial carcinoma (mUC), selecting the most appropriate option for each patient has become increasingly ...
UroToday4d
Quantifying preserved renal volume and function in patients undergoing standard partial nephrectomy vs. tumor enucleation for localized renal tumors.
Renal parenchymal volume loss from standard partial nephrectomy (SPN) is a significant prognosticator for postoperative renal function. Tumor enucleation (TE) minimizes parenchymal loss compared to ...
UroToday4d
Double Hit in Clear-Cell Renal Cell Carcinoma With Germline Pathogenic ATM Mutation and Somatic VHL Mutation.
While renal cell carcinoma (RCC) is often linked to smoking, obesity, and hypertension, hereditary forms also account for about 3% of RCC cases. Notably, NCCN guidelines identify 7 major hereditary ...
UroToday4d
Patient Demographics and Major Adverse Cardiovascular Events after Androgen Deprivation Therapy for Prostate Cancer.
The association between patient demographics and CV events after ADT using real-world data was evaluated. In addition to encompassing >30 times more patients than all previous MACE studies, this is ...
UroToday5d
ASCO 2021: Immunogenic Priming with 177Lu-PSMA-617 Plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer: A phase 1b study
(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) in the last 10 years. While the most commonly utilized ...